219 related articles for article (PubMed ID: 15655536)
1. Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline.
Yates C; Wells A; Turner T
Br J Cancer; 2005 Jan; 92(2):366-75. PubMed ID: 15655536
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
[TBL] [Abstract][Full Text] [Related]
3. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
Wells A; Souto JC; Solava J; Kassis J; Bailey KJ; Turner T
Clin Cancer Res; 2002 Apr; 8(4):1251-7. PubMed ID: 11948140
[TBL] [Abstract][Full Text] [Related]
4. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
Lamharzi N; Halmos G; Jungwirth A; Schally AV
Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
[TBL] [Abstract][Full Text] [Related]
5. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors.
Lamharzi N; Schally AV; Koppán M
Regul Pept; 1998 Oct; 77(1-3):185-92. PubMed ID: 9809814
[TBL] [Abstract][Full Text] [Related]
6. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
Buchholz S; Seitz S; Schally AV; Engel JB; Rick FG; Szalontay L; Hohla F; Krishan A; Papadia A; Gaiser T; Brockhoff G; Ortmann O; Diedrich K; Köster F
Int J Oncol; 2009 Oct; 35(4):789-96. PubMed ID: 19724914
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix.
Siejka A; Schally AV; Block NL; Barabutis N
BJU Int; 2010 Nov; 106(9):1382-8. PubMed ID: 20151966
[TBL] [Abstract][Full Text] [Related]
9. Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II, Jungwirth et al., Eur J Cancer 1997, 33(7), 1141-1148.
Limonta P; Pratesi G; Moretti RM; Montagnani Marelli M; Motta M; Dondi D
Eur J Cancer; 1998 Jun; 34(7):1134-6. PubMed ID: 9849469
[No Abstract] [Full Text] [Related]
10. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells.
Turner T; Chen P; Goodly LJ; Wells A
Clin Exp Metastasis; 1996 Sep; 14(4):409-18. PubMed ID: 8878415
[TBL] [Abstract][Full Text] [Related]
11. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
[TBL] [Abstract][Full Text] [Related]
12. STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines.
Zhou W; Grandis JR; Wells A
Br J Cancer; 2006 Jul; 95(2):164-71. PubMed ID: 16804520
[TBL] [Abstract][Full Text] [Related]
13. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals.
Xie H; Turner T; Wang MH; Singh RK; Siegal GP; Wells A
Clin Exp Metastasis; 1995 Nov; 13(6):407-19. PubMed ID: 7586799
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
[TBL] [Abstract][Full Text] [Related]
15. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Halmos G; Perez R; Fernandez JB; Vidaurre I; Szalontay L
Prostate; 2011 May; 71(7):736-47. PubMed ID: 20945403
[TBL] [Abstract][Full Text] [Related]
16. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin.
Yates CC; Shepard CR; Stolz DB; Wells A
Br J Cancer; 2007 Apr; 96(8):1246-52. PubMed ID: 17406365
[TBL] [Abstract][Full Text] [Related]
17. Cetrorelix, a gonadotropin-releasing hormone antagonist, induces the expression of melatonin receptor 1a in the gonadotropin-releasing hormone neuronal cell line GT1-7.
Ishii H; Sato S; Yin C; Sakuma Y; Kato M
Neuroendocrinology; 2009; 90(3):251-9. PubMed ID: 19641296
[TBL] [Abstract][Full Text] [Related]
18. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
19. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix.
Tang X; Yano T; Osuga Y; Matsumi H; Yano N; Xu J; Wada O; Koga K; Kugu K; Tsutsumi O; Schally AV; Taketani Y
J Clin Endocrinol Metab; 2002 Aug; 87(8):3721-7. PubMed ID: 12161501
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
Horvath JE; Toller GL; Schally AV; Bajo AM; Groot K
Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4996-5001. PubMed ID: 15044692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
